KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Safety and Immunogenicity of a New Inactivated Polio Vaccine Made From Sabin Strains: A Randomized, Double-Blind, Active-Controlled, Phase 2/3 Seamless Study.

Maria Rosario Capeding, Grace Devota Gomez-Go, Peninnah Oberdorfer, Charissa Borja-Tabora, Lulu Bravo, Josefina Carlos, Auchara Tangsathapornpong, Rattapon Uppala, Kamolwish Laoprasopwattana, Yunjeong Yang, Song Han, Orasri Wittawatmongkol

J Infect Dis 226(2) 308-318

PMID33351072
PMCIDPMC9400411
DOI10.1093/infdis/jiaa770
发表日期2020-12-22
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: A new inactivated polio vaccine made from Sabin strains (sIPV) was developed as part of the global polio eradication initiative. METHODS: This randomized, double-blind, active-controlled, phase 2/3 seamless study was conducted in 2 stages. Healthy infants aged 6 weeks were randomly assigned to receive 3 doses of 1 of 4 study vaccines at 6, 10, and 14 weeks of age (336 received low-, middle-, or high-dose sIPV, or conventional IPV [cIPV] in stage I, and 1086 received lot A, B, or C of the selected sIPV dose, or cIPV in stage II). The primary outcome was the seroconversion rate 4 weeks after the third vaccination. RESULTS: In stage I, low-dose sIPV was selected as the optimal dose. In stage II, consistency among the 3 manufacturing lots of sIPV was demonstrated. The seroconversion rates for Sabin and wild strains of the 3 serotypes after the 3-dose primary series were 95.8% to 99.2% in the lot-combined sIPV group and 94.8% to 100% in the cIPV group, proving the noninferiority of sIPV compared to cIPV. No notable safety risks associated with sIPV were observed. CONCLUSIONS: Low-dose sIPV administered as a 3-dose vaccination was safe and immunogenic compared to cIPV. CLINICAL TRIALS REGISTRATION: NCT03169725.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。